-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205

Benzinga·11/17/2026 11:51:27
Listen to the news
Cantor Fitzgerald analyst Olivia Brayer Saunders maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price target from $290 to $205.